2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

4152 Adoptive transfer of naïve T cells and memory T cells influences the efficacy of VIP-receptor antagonism in murine AML models

Stella Lee, BS, David Dong2, Callan Rose Bateman, N/A3, Charles Hsu, MD4, Jian-Ming Li, MD PhD5, Ned K. Waller, MD PhD FACP6
1 Emory College of Arts and Sciences, Atlanta, Georgia, United States
2 Emory College of Arts and Sciences, Atlanta, Georgia, United States
3 Westminster Schools of Atlanta, Atlanta, Georgia, United States
4 Winship Cancer Institute, Atlanta, Georgia, United States
5 Winship Cancer Institute, Atlanta, Georgia, United States
6 Winship Cancer Institute, Atlanta, Georgia, United States

Introduction: Acute myeloid leukemia (AML) remains difficult to treat, and immune checkpoint blockade has shown limited efficacy compared with solid tumors. Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide that inhibits T-cell activation, making VIP receptor blockade a potential strategy to enhance anti-tumor immunity. We hypothesized that combining adoptive T-cell transfer with immune checkpoint blockade, including VIP receptor antagonism, would further improve anti-leukemia efficacy.

Methods: Two murine myeloid neoplasm models were studied. C57BL/6 mice received intravenous C1498 leukemia cells (1×106), and DBA/2J mice received subcutaneous P815 mastocytoma cells (1×105). Tumor-bearing mice (n=10/group) were randomized to treatment. P815-bearing mice received control, CAMV-01 (6 nmol weekly), anti-PD-1 (200 μg twice weekly), or both agents. In a separate experiment, mice received control, CAMV-01 (6 nmol twice weekly), or CAMV-01 plus adoptive transfer of 1×106 memory T cells from mice that had eradicated leukemia following CAMV-01 treatment. C1498-bearing mice received control, naïve T-cell transfer, CAMV-01 plus anti-PD-1, or CAMV-01 plus anti-PD-1 with naïve T-cell transfer. Therapy began 7 days after tumor inoculation and continued for 2 weeks. Peripheral blood was analyzed by multiparameter flow cytometry to assess T-cell activation, differentiation, and checkpoint expression.

Results: In the P815 model, CAMV-01 plus anti-PD-1 produced greater survival than either monotherapy. By day 29, all control mice had died, whereas 60% of combination-treated mice remained alive through day 60 (p<0.0001), compared with 20% receiving anti-PD-1 alone and 10% receiving CAMV-01 alone. CAMV- 01 combined with memory T-cell transfer resulted in 40% survival and prolonged median survival from 25 to 45 days. Baseline tumor volumes were comparable across groups (55.3±3.8 mm³). Combination therapy of immune check-point blockade with memory T cells achieved the greatest tumor control, with 75% relative reduction in tumor-volume compared with 66% for memory T-cell transfer alone and 40% for CAMV-01 alone. CAMV-01 alone, memory T-cell transfer alone, and combination therapy reduced circulating PD-1+ CD4+ memory T cells by 44%, 40%, and 70%, respectively. Memory T-cell transfer alone also increased CD4+ and CD8+ effector-memory T cells 8-fold and 4-fold, respectively, versus controls. In the C1498 model, CAMV-01 plus anti-PD-1 with or without naïve T-cell transfer produced only modest survival benefit. By day 29 all control mice had died, whereas 20% of mice receiving naïve T-cell transfer alone or combined therapy survived; CAMV-01 plus anti-PD-1 alone produced 10% survival. Drug treatment increased activated CD4+ and CD8+ T cells by 64% relative to controls, while naïve T-cell transfer alone increased activation by 40%. Unexpectedly, combining naïve T-cell transfer with CAMV-01 plus anti-PD-1 reduced activated T-cell frequencies by 62% compared with either treatment alone.

Conclusions: The efficacy of adoptive T-cell therapy depended on the differentiation state and antigen experience of transferred cells. Naïve T-cell transfer provided minimal therapeutic benefit in the C1498 model and attenuated treatment-associated T-cell activation, suggesting competition with endogenous tumor-reactive T cells for activation or homeostatic signals. In contrast, adoptive transfer of tumor-experienced memory T cells significantly improved survival and tumor control in the P815 model, while reducing PD-1+ memory T cells and expanding effector-memory populations. Although combination therapy increased exhaustion-marker expression relative to memory-cell transfer alone, it produced the greatest tumor regression, consistent with a more robust and sustained anti-tumor immune response. These findings support combining VIP receptor blockade with adoptive transfer of tumor-reactive memory T cells as a promising immunotherapeutic strategy for AML.

Stella Lee, BS: No relevant conflicts of interest to declare.